Gilead
Gilead secures senior head from Genentech
December 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Gilead, Philippe Bishop
Dr Philippe Bishop is joining the California-based biopharma firm Gilead from Genentech to be the company’s senior vice president of …
Gilead sued over Sovaldi price
December 15, 2014Sales and Marketing BMS, Gilead, NICE, harvoni, hep C, septa, sofosbuvir, sovaldi
A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …
Global drug spending set to top $1 trillion
November 20, 2014Sales and Marketing Gilead, IMS, Kadcyla, Perjeta, drugs, hepatitis C, sovaldi, spend
Worldwide spending on drugs will reach over $1 trillion in 2014 and $1.3 trillion by 2018, according to a new …
Gilead gets Harvoni boost for Europe
November 20, 2014Sales and Marketing EU, Gilead, HCV, harvoni, hepc, ledipasvir, sofosbuvir, svaldi
Gilead Sciences’ new hepatitis C (HCV) tablet Harvoni has been approved across the European Union to treat the majority of …
BMS claims advance with hepatitis C regimen
November 10, 2014Research and Development, Sales and Marketing BMS, Gilead, HCV, dcv-trio, hep C, hepatitis C, liver, sovaldi
Bristol-Myers Squibb has reported data for its hepatitis C virus cocktail that it says outperforms even newer all-oral therapies in …
Sovaldi misses estimates but still makes history
October 29, 2014Research and Development, Sales and Marketing FDA, Gilead, harvoni, hep C, sofosbuvir, sovaldi
The trajectory of Gilead’s new hep C pill Sovaldi has slowed but the drug is still on course to break …
Gilead to shift plant and expand US manufacturing
September 30, 2014Manufacturing and Production AmBisome, Cayston, Gilead, San Dimas, Viread, california, manufacturing
Gilead Sciences will move its US manufacturing plant about 15 minutes down the road to a 23-acre site in the …
Sovaldi combo sees CHMP green light
September 29, 2014Sales and Marketing CHMP, EU, Gilead, HCV, harvoni, hep C, sovaldi
The CHMP is recommending that Gilead’s new combination hepatitis C drug therapy Harvoni should be approved for use across the …
Gilead’s blood cancer pill approved in Europe
September 22, 2014Sales and Marketing CLL, Gilead, blood cancer, fl, idelalisib, oncology, zydelig
Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …
Gilead allows generic prices for Sovaldi
September 16, 2014Manufacturing and Production, Sales and Marketing Gilead, hep C, hepatitis C, sofosbuvir, sovaldi
Gilead will allow Indian generic drug firms to make cheap copies of its new hepatitis C pill Sovaldi in an …
Vertex ditches its once-stellar hep C drug
August 14, 2014Sales and Marketing Gilead, Incivek, Vertex, hep C, sovaldi
Vertex will stop selling its once-blockbuster hepatitis C drug in the US this autumn after being crushed by new therapies. …
Roche’s blood cancer drug gains EU approval
July 29, 2014Research and Development, Sales and Marketing CLL, Cancer, Gilead, Janssen, Roche
The European Commission has approved Roche’s new leukaemia drug Gazyvaro (obinutuzumab) as competition for the blood cancer market heats up. …
EMA approvals for rival blood cancer drugs
July 27, 2014Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig
Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …
FDA approves Gilead’s blood cancer drug
July 24, 2014Research and Development, Sales and Marketing Cancer, FDA, Gilead, blood, follicular lymphoma and small lymphocytic lymphoma, lymphocytic leukaemia, sovaldi, zydelig
The Food and Drug Administration has approved Gilead Sciences new treatment Zydelig (idelalisib) to treat three types of blood cancer. …
Sovaldi scores in HIV patients
July 21, 2014Sales and Marketing Gilead, HIV, JAMA, hep C, hepatitis C, sovaldi
Patients with HIV and hepatitis C virus (HCV) have responded well to a combination of Gilead Sciences’ Sovaldi and ribavirin …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
